On May 13, 2025, Septerna, Inc. announced a collaboration with Novo Nordisk to develop small molecule therapies for metabolic diseases, securing an upfront payment of $195 million and potential payments exceeding $2.2 billion. The agreement allows Novo to manage further development and commercialization costs for various drug candidates, with profit-sharing options for Septerna.